Rytary (Carbidopa/Levodopa) Patent Expiration, LOE Window & CMS Spending

Rytary (Carbidopa/Levodopa) by Amneal Pharmaceuticals: FDA Orange Book LOE 2028-12-26, 18 AB generics, $278.1M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmneal Pharmaceuticals
FDA Application & PathwayN203312 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-12-26
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$278.1M
2024 Medicare Part D Spend$271.8M
2024 Medicaid Spend$6.3M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.0% 2-yr change)